Respiratory Mortality in COPD: Fixed Ratio versus Lower Limit of Normal in Smokers

Surya P Bhatt; Sandeep Bodduluri; Mark T Dransfield; MeiLan K Han; Elizabeth A Regan; Wassim A Labaki; Spyridon Fortis; Edwin K Silverman; Arie Nakhmani

doi:10.1093/ajrccm/aamag076

Back

Respiratory Mortality in COPD: Fixed Ratio versus Lower Limit of Normal in Smokers

Journal article

Peer reviewed

Respiratory Mortality in COPD: Fixed Ratio versus Lower Limit of Normal in Smokers

Surya P Bhatt, Sandeep Bodduluri, Mark T Dransfield, MeiLan K Han, Elizabeth A Regan, Wassim A Labaki, Spyridon Fortis, Edwin K Silverman and Arie Nakhmani

American journal of respiratory and critical care medicine, Vol.212(5), pp.1028-1030

05/2026

DOI: 10.1093/ajrccm/aamag076

PMCID: PMC13160943

PMID: 41738217

View Online

Abstract

no abstract

Airflow Obstruction

Respiratory Mortality

Chronic Obstructive Pulmonary Disease

Details

Title: Subtitle: Respiratory Mortality in COPD: Fixed Ratio versus Lower Limit of Normal in Smokers
Creators: Surya P Bhatt - University of Alabama at Birmingham
Sandeep Bodduluri - University of Alabama at Birmingham
Mark T Dransfield - University of Alabama at Birmingham
MeiLan K Han - University of Michigan
Elizabeth A Regan - National Jewish Health
Wassim A Labaki - University of Michigan
Spyridon Fortis - University of Iowa
Edwin K Silverman - Brigham and Women's Hospital
Arie Nakhmani - University of Alabama at Birmingham
Resource Type: Journal article
Publication Details: American journal of respiratory and critical care medicine, Vol.212(5), pp.1028-1030
DOI: 10.1093/ajrccm/aamag076
PMID: 41738217
PMCID: PMC13160943
NLM abbreviation: Am J Respir Crit Care Med
ISSN: 1535-4970
eISSN: 1535-4970
Publisher: OXFORD UNIV PRESS; OXFORD
Grant note: GlaxoSmithKline Pfizer National Institutes of Health: 75N92023D00011 Novartis The National Heart, Lung, and Blood Institute Bayer Pharmaceuticals Boehringer-Ingelheim COPD Foundation Genentech NHLBI: R01 HL151421, K01HL163249 Sunovion Industry Advisory Committee AstraZeneca The COPDGene study: NCT00608764
This work was supported by The National Heart, Lung, and Blood Institute (NHLBI) R01 HL151421 (SPB & AN), and NHLBI K01HL163249 (SB). The COPDGene study (NCT00608764) is supported by grants from the NHLBI (U01HL089897 and U01HL089856), by National Institutes of Health (NIH) contract 75N92023D00011, and by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer and Sunovion. The funders did not have any role in the analyses or presentation of these findings.
Language: English
Electronic publication date: 02/21/2026
Date published: 05/2026
Academic Unit: Pulmonary, Critical Care, and Occupational Medicine; Internal Medicine
Record Identifier: 9985139467302771

Metrics

6 Record Views

See more details